Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age | Zendy

Natasha Halasa | Zendy; Michael A. Gerber | Zendy; Andrea A. Berry | Zendy; Edwin L. Anderson | Zendy; Patricia Winokur | Zendy; Harry Keyserling | Zendy; Allison Ross Eckard | Zendy; Heather Hill | Zendy; Mark Wolff | Zendy; Monica McNeal | Zendy; Kathryn M. Edwards | Zendy; David I. Bernstein | Zendy

Open Access

Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age

Author(s) -

Natasha Halasa,

Michael A. Gerber,

Andrea A. Berry,

Edwin L. Anderson,

Patricia Winokur,

Harry Keyserling,

Allison Ross Eckard,

Heather Hill,

Mark Wolff,

Monica McNeal,

Kathryn M. Edwards,

David I. Bernstein

Publication year - 2014

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piu061

Subject(s) - medicine , immunogenicity , trivalent influenza vaccine , titer , cohort , hemagglutination assay , influenza vaccine , adverse effect , immunology , antibody , vaccination , pediatrics

Children 6 through 35 months of age are recommended to receive half the dose of influenza vaccine compared with older children and adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research